YU47903B - Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli - Google Patents

Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli

Info

Publication number
YU47903B
YU47903B YU196488A YU196488A YU47903B YU 47903 B YU47903 B YU 47903B YU 196488 A YU196488 A YU 196488A YU 196488 A YU196488 A YU 196488A YU 47903 B YU47903 B YU 47903B
Authority
YU
Yugoslavia
Prior art keywords
salts
controlled
buspiron
procedure
oral formulation
Prior art date
Application number
YU196488A
Other languages
English (en)
Other versions
YU196488A (en
Inventor
A.G.M. Nicklasson
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of YU196488A publication Critical patent/YU196488A/xx
Publication of YU47903B publication Critical patent/YU47903B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

POSTUPAK ZA PRIPREMANJE ORALNE FORMULACIJE ZA KONTROLISANO/PRODUŽENO OSLOBADJANJE BUSPIRONA I NJEGOVIH SOLI, koja ima ukupno in vitro vreme rastvaranja izmedju 6 i 24 časa za najmanje 80% sadržaja buspirona, naznačen time, što je buspiron ili neka njegova so ugradjen u jedan nosač koji ispušta buspiron ili jednu njegovu so u navedenom in vitro vremenu rastvaranja. Prijava sadrži još 9 zavisnih zahteva.
YU196488A 1987-10-22 1988-10-20 Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli YU47903B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8704097A SE8704097D0 (sv) 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof

Publications (2)

Publication Number Publication Date
YU196488A YU196488A (en) 1990-04-30
YU47903B true YU47903B (sh) 1996-05-20

Family

ID=20369959

Family Applications (1)

Application Number Title Priority Date Filing Date
YU196488A YU47903B (sh) 1987-10-22 1988-10-20 Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli

Country Status (21)

Country Link
EP (1) EP0313535B1 (sh)
JP (1) JP2674170B2 (sh)
KR (1) KR970004906B1 (sh)
AT (1) ATE108997T1 (sh)
AU (1) AU604585B2 (sh)
CY (1) CY1814A (sh)
DE (1) DE3850844T2 (sh)
DK (1) DK294489A (sh)
ES (1) ES2056955T3 (sh)
FI (1) FI100303B (sh)
HK (1) HK21295A (sh)
HU (1) HU204998B (sh)
IE (1) IE64705B1 (sh)
IL (1) IL88020A (sh)
NO (1) NO892512D0 (sh)
NZ (1) NZ226604A (sh)
PT (1) PT88820B (sh)
SE (1) SE8704097D0 (sh)
WO (1) WO1989003676A1 (sh)
YU (1) YU47903B (sh)
ZA (1) ZA887624B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
PL192273B1 (pl) * 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
CN117257747B (zh) * 2023-11-21 2024-01-30 泊诺(天津)创新医药研究有限公司 一种盐酸丁螺环酮片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
SE353229B (sh) * 1970-06-04 1973-01-29 Haessle Ab
US4182703A (en) * 1978-01-09 1980-01-08 Eastman Kodak Company Biheterocyclic ultraviolet stabilizers and their use in organic compositions
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone

Also Published As

Publication number Publication date
NZ226604A (en) 1991-07-26
ATE108997T1 (de) 1994-08-15
NO892512L (no) 1989-06-16
ZA887624B (en) 1989-06-28
KR890701087A (ko) 1989-12-19
DK294489D0 (da) 1989-06-15
AU604585B2 (en) 1990-12-20
HK21295A (en) 1995-02-24
DE3850844T2 (de) 1994-12-08
NO892512D0 (no) 1989-06-16
AU2623688A (en) 1989-05-23
YU196488A (en) 1990-04-30
FI100303B (fi) 1997-11-14
DK294489A (da) 1989-06-15
EP0313535B1 (en) 1994-07-27
EP0313535A1 (en) 1989-04-26
PT88820B (pt) 1993-01-29
CY1814A (en) 1995-10-20
SE8704097D0 (sv) 1987-10-22
JPH02501744A (ja) 1990-06-14
FI893017A (fi) 1989-06-20
IL88020A0 (en) 1989-06-30
DE3850844D1 (de) 1994-09-01
HUT54495A (en) 1991-03-28
IL88020A (en) 1993-08-18
WO1989003676A1 (en) 1989-05-05
KR970004906B1 (ko) 1997-04-08
HU204998B (en) 1992-03-30
HU886266D0 (en) 1991-01-28
JP2674170B2 (ja) 1997-11-12
IE64705B1 (en) 1995-08-23
ES2056955T3 (es) 1994-10-16
IE883177L (en) 1989-04-22
FI893017A0 (fi) 1989-06-20

Similar Documents

Publication Publication Date Title
DK653688D0 (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
EP0285008A3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
NO874955L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heteroaromatiske aminderivater.
NO172580C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider
YU47903B (sh) Postupak za pripremanje oralne formulacije za kontrolisano/produženo oslobadjanje buspirona i njegovih soli
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
MX10059A (es) Procedimiento para la preparacion de antagonistas de leucotrienos novedosos y producto obtenido
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
NO874850D0 (no) Fremgangsmaate for fremstilling av benzotiadiazinforbindelser og farmasoeytisk akseptable salter derav.
DK122191D0 (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
NO172490C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-disubstituerte piperazinderivater
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
NO169648C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater
NO169835C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive katecholkarboksylderivater
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
NO870950D0 (no) Fremgangsmaate for fremstilling av et stabilt injiserbart farmasoeytisk preparat.
DK222588A (da) 5-quinoxalyl-imidazolidin-2,4-dioner, deres fremstilling og anvendelse som laegemidler
NO172120C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoxazoler
DE3367216D1 (de) 3-deazaguanine sulphonic acid salts
NO171210C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenofuran-derivater
NO891678D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.
NO890502D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.